You are here

AG-013736 (Axitinib) In Patients With Poor Prognosis Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS)

Last updated on March 15, 2019

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Houston, Texas, 77030 United States
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Poor prognosis AML or MDS

- Histological confirmation of diagnosis

- White blood cell count less than or equal to 30,000/mm3

- Adequate hepatic and renal function documented within 14 days prior to registration

- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2

- No evidence of preexisting uncontrolled hypertension

- Not a suitable candidate for chemotherapy

- No prior systemic chemotherapy treatment for AML or MDS or treatment with an
anti-angiogenesis agent

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Patients must not have exclusion criteria.

- Candidate for chemotherapy

- Patients with AML M3 (acute promyelocytic leukemia)

- Conditions that might confound the evaluation of safety or efficacy or increase
patient risk.

NCT00071006
Pfizer
Completed
AG-013736 (Axitinib) In Patients With Poor Prognosis Acute Myeloid Leukemia (AML) Or Myelodysplastic Syndrome (MDS)

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome
NCT00071006
All Genders
18+
Years
Houston, Texas
Myelodysplastic Syndrome, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
NCT02367456
All Genders
18+
Years
Multiple Sites
Acute Myeloid Leukemia, Myelodysplastic Syndrome, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
NCT01399840
All Genders
18+
Years
Multiple Sites

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now